Prediction Case File
YouTubeEvaluation Complete

Friends! In this video, I'm going to discuss 2 growth stocks that im buying in this market.

2 extracted signals · 2 resolved · 0 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
24 Nov 2025, 22:44 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to discuss 2 growth stocks that im buying in this market.
Source overview

AI-generated source summary

The analysis covers SOFI, HIMS, and NVDA. SOFI and HIMS are identified as undervalued growth stocks with significant upside potential, despite recent price drops and volatility. SOFI's strong member growth and transition to a fee-based model are highlighted, while HIMS's rapid expansion across various health sectors and its lean business model are seen as positive indicators. NVDA is noted for its recent performance with a forecast for continued bearish momentum, although the speaker does not provide specific entry or exit points for NVDA.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Evaluation Complete
Signals
2
Extracted from this source
Open
0
Still being tracked
Successful
0
Resolved successfully
Failed
2
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
0%
2 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. First prediction resolved

    The first evaluable outcome in this case reached a terminal result.

  3. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  4. Market predictions extracted

    2 eligible signals linked to this case.

  5. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  6. Case evaluation completed

    All evaluable predictions in this case reached terminal outcomes.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail